D
LENZ Therapeutics, Inc. LENZ
$39.68 -$0.32-0.80% NASDAQ
Recommendation
Prev Close
$39.68
Volume
219
Avg Vol (90D)
378,680
Market Cap
$1.13B
Dividend & Yield
--
52-Week Range
$16.54 - $41.70
P/E (TTM)
--
EPS (TTM)
-$1.90
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences LENZ Stock News
8/25/2025 - GuruFocus
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
8/25/2025 - GuruFocus
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
8/25/2025 - Globe Newswire
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $49.60 Average Price Target from Brokerages
8/22/2025 - Ticker Report
Lord Abbett & CO. LLC Makes New Investment in LENZ Therapeutics, Inc. (NASDAQ:LENZ)
8/19/2025 - MarketBeat
First Week of April 2026 Options Trading For Lenz Therapeutics
8/18/2025 - Stock Options Channel
LENZ Therapeutics (NASDAQ:LENZ) Sees Unusually-High Trading Volume - Time to Buy?
8/17/2025 - MarketBeat
LENZ Therapeutics (LENZ, $37.85) RSI Indicator left the overbought zone on August 15, 2025
8/16/2025 - Tickeron - Stocks
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 7.6% - Should You Sell?
8/14/2025 - MarketBeat
LENZ Therapeutics (LENZ, $39.36) price may drop as it broke higher Bollinger Band on Aug 13, 2025
8/14/2025 - Tickeron - Stocks
LENZ Therapeutics (LENZ, $39.36) RSI Indicator left the overbought zone on August 13, 2025
8/14/2025 - Tickeron - Stocks
LENZ Therapeutics (LENZ, $36.33) RSI Indicator left the overbought zone on August 12, 2025
8/13/2025 - Tickeron - Stocks
LENZ Therapeutics (NASDAQ:LENZ) Reaches New 52-Week High - Still a Buy?
8/12/2025 - MarketBeat
Why LENZ Therapeutics (LENZ) Is Up 32.2% After FDA Approves First Aceclidine Eye Drop for Presbyopia
8/12/2025 - Simply Wall St
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 3.6% - Time to Sell?
8/5/2025 - MarketBeat
TD Asset Management Inc Has $895,000 Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)
8/5/2025 - MarketBeat
Lenz Therapeutics (LENZ) Shares Cross Below 200 DMA
8/4/2025 - Market News Video
HC Wainwright Brokers Boost Earnings Estimates for LENZ
8/4/2025 - MarketBeat
Lenz Therapeutics (LENZ) Target Price Hiked Following FDA Approval
8/3/2025 - GuruFocus
Lenz Therapeutics price target raised to $53 from $44 at BofA
8/3/2025 - TipRanks Financial Blog
Lenz Therapeutics price target raised by $9 at BofA, here's why
8/3/2025 - The Fly
LENZ Therapeutics (NASDAQ:LENZ) Sees Strong Trading Volume on Analyst Upgrade
8/2/2025 - MarketBeat
The volume for LENZ Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 435% of the 65-Day Volume Moving Average
8/2/2025 - Tickeron - Stocks
William Blair Analysts Lower Earnings Estimates for LENZ
8/2/2025 - MarketBeat
Lenz Therapeutics (LENZ) Sees Raised Price Target After FDA Approval
8/1/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$5.00M
EBITDA (TTM)
-$61.87M
EBIT (TTM)
-$61.96M
Net Income (TTM)
-$52.40M
Balance Sheet
Total Assets (Q)
$217.33M
Total Debt (Q)
$1.05M
Total Liabilities (Q)
$10.97M
Book Value Per Share (Q)
$7.24
Cash Flow
Cash from Operations (TTM)
-$47.22M
Cash from Investing (TTM)
-$55.61M
Cash from Financing (TTM)
$56.40M
Net Change in Cash (TTM)
-$46.43M
Filings
Filing Date
Wednesday, July 30, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
--
7-Day Total Return
4.83%
30-Day Total Return
21.16%
60-Day Total Return
35.89%
90-Day Total Return
72.07%
Year to Date Total Return
40.26%
1-Year Total Return
80.36%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 09, 2025 - $16.54
52-week High
Aug 15, 2025 - $41.70
Valuation
Market Cap
$1.13B - Small Cap
Enterprise Value
$923.29M
Price/Sales (TTM)
222.92
Price/Book (Q)
5.48
Dividends and Shares
Shares Outstanding
28.08
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.lenz-tx.com
Phone Number
(858) 925-7000
Address
201 Lomas Santa Fe Drive
Solana Beach, CA 92075
Country
United States
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates... more
NASDAQ 08/25/2025 4:00PM Eastern Quotes delayed